VisionCare Ophthalmic Technologies is a technology company.
VisionCare Ophthalmic Technologies has raised $31.0M across 1 funding round.
VisionCare Ophthalmic Technologies has raised $31.0M in total across 1 funding round.
VisionCare Ophthalmic Technologies has raised $31.0M in total across 1 funding round.
VisionCare Ophthalmic Technologies's investors include Norwest Venture Partners.
VisionCare Ophthalmic Technologies (now known as Samsara Vision, Inc.) is a specialty medical device company focused on developing implantable ophthalmic devices to improve vision for patients with advanced retinal disorders, particularly late-stage age-related macular degeneration (AMD). Their flagship product, the Implantable Miniature Telescope (IMT), is the first and only FDA-approved implantable device shown to improve vision and quality of life for individuals suffering from the most severe, irreversible form of AMD. The company primarily serves patients with untreatable retinal diseases and healthcare providers in ophthalmology, addressing the critical problem of central vision loss that cannot be corrected by conventional treatments like glasses or surgery. Samsara Vision has demonstrated growth momentum through ongoing clinical studies, product innovation such as the smaller-incision SING IMT, and expanding reimbursement coverage internationally[1][2][3].
Founded in 1997 by Dr. Isaac Lipshitz and Yossi Gross, VisionCare emerged from the vision of creating a novel implantable device to restore sight in patients with end-stage AMD. Dr. Lipshitz, an ophthalmologist, invented the IMT to address the unmet need for vision restoration in this population. Early traction came from FDA approval of the IMT and successful clinical outcomes that validated the device’s efficacy. Over time, the company evolved its focus to include next-generation devices and global market expansion, rebranding as Samsara Vision to emphasize rejuvenation of eyesight and patient quality of life[1][2][3][4][5].
VisionCare/Samsara Vision rides the growing trend of implantable medical devices that restore function lost to chronic diseases, here targeting a leading cause of blindness in older adults. The timing is critical as the aging global population increases AMD prevalence, creating urgent demand for effective treatments. Market forces such as advances in microsurgery, regulatory approvals, and expanding reimbursement frameworks favor adoption of innovative ophthalmic implants. By pioneering implantable telescopes, the company influences the broader ecosystem by setting new standards for vision restoration and inspiring further innovation in retinal prosthetics and implantable devices[1][2][3][5].
Looking ahead, Samsara Vision is positioned to expand the reach of its SING IMT device through ongoing clinical trials, regulatory approvals, and reimbursement gains worldwide. Trends shaping their journey include an aging population, increasing prevalence of AMD, and technological advances in miniaturized implantable devices. Their influence may grow as they enable hundreds of thousands more patients to regain functional vision, potentially catalyzing broader adoption of implantable ophthalmic technologies. Continued innovation, global market penetration, and strong partnerships will be key to sustaining momentum and fulfilling their mission to restore sight and improve quality of life for patients with untreatable retinal disorders[2][3][5].
VisionCare Ophthalmic Technologies has raised $31.0M across 1 funding round. Most recently, it raised $31.0M Series E in January 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2011 | $31.0M Series E | Norwest Venture Partners |